Evidence map›Paper›PMID 36941528›Full record

ArticleJournal of clinical laboratory analysis2023

Potent SARS-CoV2-specific T-cell response in asymptomatic hemodialysis patients with hidden COVID-19 infection history.

Jalal Etemadi, Roza Motavalli, Seyed Alireza Mirghaffari, Mohammad Sadegh Soltani-Zangbar, Mahsa Hajivalili, Javad Ahmadian Heris, Bahram Niknafs, Sepideh Zununi, Mohammadreza Sadeghi, Sadraddin Rasi Hashemi and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical laboratory analysis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Jalal EtemadiKidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Roza MotavalliDepartment of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Seyed Alireza MirghaffariKidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mohammad Sadegh Soltani-ZangbarStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Mahsa HajivaliliBehbahan Faculty of Medical Sciences, Behbahan, Iran.
Javad Ahmadian HerisDepartment of Allergy and Clinical Immunology, Pediatric Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
Bahram NiknafsKidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Sepideh ZununiKidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mohammadreza SadeghiDepartment of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.
Sadraddin Rasi HashemiKidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Hamid Tayebi KhosroshahiKidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mehdi YousefiStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID https://orcid.org/0000-0003-0099-6728
Tabriz University of Medical Sciences · IR

Funding

Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 67507
6 · The paper itself

Abstract

backgroundCOVID-19-related immune responses in patients with end-stage renal disease (ESRD) are characterized in detail by the humoral response, but their cellular immunity has not been clarified. Here, we evaluated virus-specific T cells in parallel with serology-related tests.

methodsIn this study, 104 ESRD patients at the hemodialysis ward of Imam Reza hospital at Tabriz (Iran) were enrolled. After blood sampling, SARS-CoV2-specific humoral and cellular immune responses were evaluated by SARS-CoV2-specific IgM/IgG ELISA and peptide/MHCI-Tetramers flow cytometry, respectively.

resultsOur results showed that 14 (13.5%) and 45 (43.3%) patients had specific SARS-CoV2 IgM and IgG in their sera, respectively. Immunophenotyping for SARS-CoV2-specific CD8

conclusionDespite not having clinical symptoms, a high rate of SARS-CoV2-specific T-cell response in asymptomatic ESRD patients may reveal a high burden of asymptomatic COVID-19 infection in these patients.

Indexed as

COVID-19Kidney Failure, ChronicAntibodies, ViralHumansImmunoglobulin GImmunoglobulin MRenal DialysisRNA, ViralSARS-CoV-2T-LymphocytesAntibodies, ViralImmunoglobulin GImmunoglobulin MRNA, ViralantibodyCOVID-19hemodialysisHLA-I-tetramerSARS-CoV2

Identifiers

PMID36941528
PMCPMC10098065
OpenAlexW4328048936

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.